BioMarin Pharmaceutical Inc. BMRN
Updated: 7 Sep 2026
No signal published yet
We already track BioMarin Pharmaceutical and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow BioMarin Pharmaceutical Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow BioMarin Pharmaceutical free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On September 1, 2026, BioMarin closed its acquisition of Alesta Therapeutics to acquire the oral clinical asset ALE1 for hypophosphatasia. On August 31, 2026, the company finalized a global patent settlement with Ascendis Pharma, securing ongoing royalty payments on Yuviwel sales. On August 6, 2026, BioMarin reported second-quarter 2026 revenue of $990 million, representing a 20% year-over-year increase.
What Firelda Watch includes for BioMarin Pharmaceutical Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow BioMarin Pharmaceutical Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow BioMarin Pharmaceutical free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more